Ocrevus Zunovo FDA Approval History
FDA Approved: Yes (First approved September 13, 2024)
Brand name: Ocrevus Zunovo
Generic name: ocrelizumab & hyaluronidase-ocsq
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Multiple Sclerosis
Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) is a CD20-directed cytolytic antibody and hyaluronidase combination used for the treatment of people with relapsing and progressive multiple sclerosis.
- Ocrevus Zunovo is indicated for:
- relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- primary progressive MS, in adults.
Development timeline for Ocrevus Zunovo
| Date | Article |
|---|---|
| Sep 17, 2024 | Approval FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.